Evidence map›Paper›PMID 35184977›Full record

ArticleJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy2022

Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 panel, a rapid multiplex PCR method for the diagnosis of COVID-19.

Masahiro Ishikane, Hiroyuki Unoki-Kubota, Ataru Moriya, Satoshi Kutsuna, Honami Ando, Yasushi Kaburagi, Tetsuya Suzuki, Noriko Iwamoto, Moto Kimura, Norio Ohmagari

Open access · greenAbstract read
In one paragraph

Article in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Trend ofIJID regions · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Recent progress on rapid diagnosis of COVID-19 by point-of-care testing platforms.Chinese chemical letters = Zhongguo hua xue kuai bao · 2023
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Masahiro IshikaneDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: ishikanemasahiro@gmail.com.
Hiroyuki Unoki-KubotaDepartment of Diabetic Complications, Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Ataru MoriyaClinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan.
Satoshi KutsunaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Department of Infection Control, Graduate School of Medicine, Osaka University, Japan.
Honami AndoClinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan.
Yasushi KaburagiDepartment of Diabetic Complications, Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Tetsuya SuzukiDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Noriko IwamotoDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Moto KimuraCenter for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Norio OhmagariDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
National Center for Global Health and Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRapid, simple, and accurate methods are required to diagnose coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to evaluate the performance of the QIAstat-Dx Respiratory SARS-CoV-2 Panel (QIAstat-SARS-CoV-2), a rapid multiplex PCR assay for SARS-CoV-2 detection.

methodsNasopharyngeal swabs (NPS) that were obtained from patients with COVID-19 who were diagnosed at the National Center for Global Health and Medicine were used in this study. When the NPS samples were found to be negative for SARS-CoV-2 after treatment, they were used as negative samples. We evaluated the performance of the QIAstat-SARS-CoV-2 comparing SARS-CoV-2 detection with the National Institute of Infectious Diseases in Japan-recommended real-time polymerase chain reaction (RT-PCR) method (NIID-RT-PCR).

resultsIn total, 45 NPS samples were analyzed. The proportion of overall agreement between QIAstat-SARS-CoV-2 and NIID-RT-PCR on 45 samples was 91.0% with a sensitivity of 84.0% (21/25), specificity at 100% (20/20), negative predictive value at 83.3% (20/24), and positive predictive value at 100% (21/21). There were no patients with co-infections with pathogens other than SARS-CoV-2.

conclusionsQIAstat-SARS-CoV-2 showed a high agreement in comparison with the NIID-RT-PCR for the detection of SARS-CoV-2. The QIAstat-SARS-CoV-2 also provided a rapid and accurate diagnosis for COVID-19, even when the concurrent detection of other respiratory pathogens was desired, and therefore, has the potential to direct appropriate therapy and infection control precautions.

Indexed as

COVID-19SARS-CoV-2HumansMultiplex Polymerase Chain ReactionRespiratory SystemSensitivity and SpecificityCOVID-19DianosticsRapid testsSARS-CoV-2

Identifiers

PMID35184977
PMCPMC8825349
OpenAlexW4210885877

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.